On November 30, 2026, Exicure, Inc. agreed to sell and assign assets related to the GPC-100 program to GPCR Therapeutics USA Inc. The deal aims to transfer obligations and IP known as Burixafor, following the acquisition of GPCR USA.
On November 30, 2026, Exicure, Inc. agreed to sell and assign assets related to the GPC-100 program to GPCR Therapeutics USA Inc. The deal aims to transfer obligations and IP known as Burixafor, following the acquisition of GPCR USA.